Innovent Biologics base_Aktie

Innovent Biologics base_Umsatz 2025

Innovent Biologics base_Umsatz

١٢٫١٣ number_format_mrd CNY

components_StockPageHeader__3

1801.HK

components_StockPageHeader__4

KYG4818G1010

components_StockPageHeader__5

A2N7N8

pages_kennzahlen_[key]_[isin]__46

pages_kennzahlen_[key]_[isin]__70

components_DataTable__24components_DataTable__0components_DataTable__2
2030e٣١٫١٩25,86
2029e٢٧٫٨٥28,96
2028e٢٣٫٥٤34,26
2027e١٨٫٩٠42,67
2026e١٥٫١٣53,30
2025e١٢٫١٣66,49
2024٩٫٤٢85,60
2023٦٫٢١81,69
2022٤٫٥٦79,57
2021٤٫٢٧88,16
2020٣٫٨٤89,91
2019١٫٠٥88,08
2018٠٫٠١85100,23
2017٠٫٠٢43504,96
2016--

components_charts_RevenueChart_0

  • chart_toolbar_3y

  • chart_toolbar_5y

  • chart_toolbar_10y

  • components_charts_BaseChart_0

  • chart_toolbar_max

components_charts_RevenueChart_8
components_charts_RevenueChart_10
components_charts_RevenueChart_9
components_charts_RevenueChart_13

Innovent Biologics components_charts_RevenueChart_15

components_charts_RevenueChart_14Innovent Biologics components_charts_RevenueChart_8Innovent Biologics components_charts_RevenueChart_10Innovent Biologics components_charts_RevenueChart_9
2030e٣١٫١٩ number_format_mrd undefined0 undefined٤٫٦٧ number_format_mrd undefined
2029e٢٧٫٨٥ number_format_mrd undefined٦٫٩١ number_format_mrd undefined٣٫٢٣ number_format_mrd undefined
2028e٢٣٫٥٤ number_format_mrd undefined٥٫١٥ number_format_mrd undefined٢٫٨٧ number_format_mrd undefined
2027e١٨٫٩٠ number_format_mrd undefined٢٫٧٢ number_format_mrd undefined٢٫٥٨ number_format_mrd undefined
2026e١٥٫١٣ number_format_mrd undefined١٫٠٣ number_format_mrd undefined١٫٤٢ number_format_mrd undefined
2025e١٢٫١٣ number_format_mrd undefined٢١٨٫٢٩ number_format_mio undefined٣٥٨٫٥٦ number_format_mio undefined
2024٩٫٤٢ number_format_mrd undefined؜-٤٧٫١٧ number_format_mio undefined؜-٩٤٫٦٣ number_format_mio undefined
2023٦٫٢١ number_format_mrd undefined؜-١٫٤٧ number_format_mrd undefined؜-١٫٠٣ number_format_mrd undefined
2022٤٫٥٦ number_format_mrd undefined؜-٣٫٠٢ number_format_mrd undefined؜-٢٫١٨ number_format_mrd undefined
2021٤٫٢٧ number_format_mrd undefined؜-٢٫٦٦ number_format_mrd undefined؜-٢٫٧٣ number_format_mrd undefined
2020٣٫٨٤ number_format_mrd undefined؜-٤٢٦٫٥٠ number_format_mio undefined؜-٩٩٨٫٤٢ number_format_mio undefined
2019١٫٠٥ number_format_mrd undefined؜-١٫٧٨ number_format_mrd undefined؜-١٫٧٢ number_format_mrd undefined
2018٩٫٤٨ number_format_mio undefined؜-١٫٥٠ number_format_mrd undefined؜-٥٫٧٧ number_format_mrd undefined
2017١٨٫٥٤ number_format_mio undefined؜-٦٢٤٫٧٣ number_format_mio undefined؜-٥٦٢٫٣٢ number_format_mio undefined
20160 undefined؜-٤١٣٫٢٧ number_format_mio undefined؜-٥٠٤٫٢٠ number_format_mio undefined

components_charts_MarginsChart_0

components_charts_MarginsChart_18
  • chart_toolbar_3y

  • chart_toolbar_5y

  • chart_toolbar_10y

  • components_charts_BaseChart_0

  • chart_toolbar_max

components_charts_MarginsChart_15
components_charts_MarginsChart_17
components_charts_MarginsChart_16
components_charts_MarginsChart_19

Innovent Biologics components_charts_MarginsChart_21

Innovent Biologics components_charts_MarginsChart_15Innovent Biologics components_charts_MarginsChart_16Innovent Biologics components_charts_MarginsChart_17Innovent Biologics components_charts_MarginsChart_16
2030e٨٥٫٦٠ %0 %١٤٫٩٧ %
2029e٨٥٫٦٠ %٢٤٫٨١ %١١٫٥٩ %
2028e٨٥٫٦٠ %٢١٫٨٩ %١٢٫١٨ %
2027e٨٥٫٦٠ %١٤٫٣٧ %١٣٫٦٨ %
2026e٨٥٫٦٠ %٦٫٧٧ %٩٫٣٦ %
2025e٨٥٫٦٠ %١٫٨٠ %٢٫٩٦ %
2024٨٥٫٦٠ %؜-٠٫٥٠ %؜-١٫٠٠ %
2023٨١٫٦٩ %؜-٢٣٫٧٥ %؜-١٦٫٥٦ %
2022٧٩٫٥٧ %؜-٦٦٫١٨ %؜-٤٧٫٨٣ %
2021٨٨٫١٦ %؜-٦٢٫٢٢ %؜-٦٣٫٩١ %
2020٨٩٫٩١ %؜-١١٫١٠ %؜-٢٥٫٩٧ %
2019٨٨٫٠٨ %؜-١٦٩٫٧٦ %؜-١٦٤٫١٩ %
2018٨٥٫٦٠ %؜-١٥٬٧٧٩٫٤٠ %؜-٦٠٬٨٩٩٫٩٩ %
2017٨٥٫٦٠ %؜-٣٬٣٦٩٫٩٩ %؜-٣٬٠٣٣٫٣٣ %
2016٨٥٫٦٠ %0 %0 %

Innovent Biologics Aktienanalyse

pages_kennzahlen_[key]_[isin]__1

Innovent Biologics Inc. is an innovative biopharmaceutical company that focuses on the discovery, development, and commercialization of world-leading biological therapies. The company was founded in 2011 by a group of outstanding scientists who already had extensive experience in biological research and development. Since then, Innovent Biologics Inc. has achieved many successes and has become a significant player in the biopharmaceutical industry. Innovent Biologics' business model is based on the use of cutting-edge technology and collaboration with partners to develop and bring innovative biopharmaceuticals to the market. The company utilizes a platform technology based on a combination of protein production and antibody development to provide a strong foundation for its innovative pipeline of therapeutics. Innovent Biologics specializes in three main areas: cancer therapy, autoimmune diseases, and ophthalmology. The company has developed an impressive number of product candidates to meet the need for innovative therapeutics in these areas. In the field of cancer therapy, Innovent Biologics specializes particularly in the treatment of lung tumors. The company has successfully developed tyrosine kinase inhibitors targeting important therapy targets. Additionally, the company has also developed antibodies against cancer that stimulate the patient's immune system to fight tumor cells. Innovent Biologics is also a leader in the development of drugs for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. By identifying highly specific antibodies with therapeutic potential, the company has developed a pipeline of promising drug candidates. In the field of ophthalmology, Innovent Biologics has achieved remarkable successes. The company has developed an innovative therapeutic antibody platform specifically targeting the treatment of eye diseases. This platform allows for the optimization of the drug to better suit the eye and achieve higher efficacy. Innovent Biologics has already discovered several antibody candidates that have produced promising clinical results. In addition to its product candidates, Innovent Biologics has also formed partnerships with other industry players. The company collaborates closely with other biopharmaceutical companies to jointly develop and market innovative therapeutics. Overall, Innovent Biologics Inc. has built an impressive track record and experience in a relatively short period. It is a leading player in the development of biopharmaceuticals that have the potential to revolutionize the healthcare industry. The company has a strong pipeline of product candidates in various therapy areas, supported by innovative platform technology. Innovent Biologics is able to further expand its work through close collaboration with partners and a variety of collaborators. Innovent Biologics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

pages_kennzahlen_[key]_[isin]__85

pages_kennzahlen_[key]_[isin]__71

pages_dividenden_[isin]_index__2

components_kpi_RevenueFaqs_0

components_kpi_RevenueFaqs_1

components_kpi_RevenueFaqs_2

components_kpi_RevenueFaqs_3

components_kpi_RevenueFaqs_4

components_kpi_RevenueFaqs_5

components_kpi_RevenueFaqs_6

components_kpi_RevenueFaqs_7

components_kpi_RevenueFaqs_8

components_kpi_RevenueFaqs_9

components_kpi_RevenueFaqs_10

components_kpi_RevenueFaqs_11

components_kpi_RevenueFaqs_12

components_kpi_RevenueFaqs_13

components_kpi_RevenueFaqs_14

components_kpi_RevenueFaqs_15

components_kpi_RevenueFaqs_16

components_kpi_RevenueFaqs_17

pages_aktie_[isin]_[key]_index_0

pages_aktie_[isin]_[key]_index_1

pages_aktie_[isin]_[key]_index_2

pages_aktie_[isin]_[key]_index_3

pages_aktie_[isin]_[key]_index_4

pages_aktie_[isin]_[key]_index_5

pages_aktie_[isin]_[key]_index_6

pages_aktie_[isin]_[key]_index_7

pages_aktie_[isin]_[key]_index_8

pages_aktie_[isin]_[key]_index_9

pages_aktie_[isin]_[key]_index_10

pages_aktie_[isin]_[key]_index_14

Wann musste ich die Aktien von Innovent Biologics kaufen, um die vorherige Dividende zu erhalten?

pages_aktie_[isin]_[key]_index_15

pages_aktie_[isin]_[key]_index_16

pages_aktie_[isin]_[key]_index_18

pages_aktie_[isin]_[key]_index_19

pages_aktie_[isin]_[key]_index_20

pages_aktie_[isin]_[key]_index_21

pages_aktie_[isin]_[key]_index_22

components_kpi_Savingsplan_0